- Home
- TPVG vs MGNX Comparison
TPVG vs MGNX Comparison
Compare TPVG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- MGNX
- Stock Information
- Founded
- TPVG 2013
- MGNX 2000
- Country
- TPVG United States
- MGNX United States
- Employees
- TPVG N/A
- MGNX N/A
- Industry
- TPVG Other Consumer Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- MGNX Health Care
- Exchange
- TPVG Nasdaq
- MGNX Nasdaq
- Market Cap
- TPVG 316.4M
- MGNX 257.3M
- IPO Year
- TPVG N/A
- MGNX 2013
- Fundamental
- Price
- TPVG $8.04
- MGNX $3.22
- Analyst Decision
- TPVG Hold
- MGNX Buy
- Analyst Count
- TPVG 6
- MGNX 11
- Target Price
- TPVG $7.81
- MGNX $8.57
- AVG Volume (30 Days)
- TPVG 314.2K
- MGNX 742.0K
- Earning Date
- TPVG 11-06-2024
- MGNX 11-05-2024
- Dividend Yield
- TPVG 18.90%
- MGNX N/A
- EPS Growth
- TPVG N/A
- MGNX N/A
- EPS
- TPVG 0.27
- MGNX N/A
- Revenue
- TPVG $115,271,000.00
- MGNX $141,329,000.00
- Revenue This Year
- TPVG N/A
- MGNX $119.63
- Revenue Next Year
- TPVG N/A
- MGNX N/A
- P/E Ratio
- TPVG $29.14
- MGNX N/A
- Revenue Growth
- TPVG N/A
- MGNX 16.68
- 52 Week Low
- TPVG $6.44
- MGNX $2.95
- 52 Week High
- TPVG $11.58
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- TPVG 71.35
- MGNX 37.73
- Support Level
- TPVG $7.83
- MGNX $3.22
- Resistance Level
- TPVG $8.02
- MGNX $5.10
- Average True Range (ATR)
- TPVG 0.20
- MGNX 0.35
- MACD
- TPVG 0.07
- MGNX -0.10
- Stochastic Oscillator
- TPVG 95.57
- MGNX 2.12
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).